Civic Intelligence

AIDS Treatment Activists Coalition

990EZ • Fiscal year 2017 • EIN 57-1168208

Jan 01, 2017 to Dec 31, 2017 • Filed on Nov 02, 2018

Organization Profilewww.aidstreatmentactivists.org
PO Box 9153Denver, CO 80209

(303) 777-7208

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on this filing.

Source year 2017

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on this filing.

Source year 2017

Net Margin

12th percentile

-30%

Higher net margin than 12% of similar nonprofits.

2017 filings • 501(c)3 • <$500k nonprofits • Source year 2017

Top Officer Pay

76th percentile

$0

Higher top officer pay than 76% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2017 filings • 501(c)3 • <$500k nonprofits • Source year 2017

Asset Growth

37th percentile

-4.1%

Faster asset growth than 37% of similar nonprofits.

2017 filings • 501(c)3 • <$500k nonprofits • Annualized from 2016 to 2017

Revenue Growth

42nd percentile

-3.7%

Faster revenue growth than 42% of similar nonprofits.

2017 filings • 501(c)3 • <$500k nonprofits • Annualized from 2016 to 2017

Balance Sheet
Liabilities / AssetsScore unavailable

Assets

Down

$256,132

Down $11,009 (-4.1%) from 2016

Net Assets

Down

$256,132

Down $11,009 (-4.1%) from 2016

Liabilities

-

No earlier filing loaded for comparison.

Revenue And Expenses
Liabilities / RevenueScore unavailableNet Margin12th percentile

Revenue

Down

$36,304

Down $1,403 (-3.7%) from 2016

Expenses

Up

$47,313

Up $31,601 (+201%) from 2016

Net Income

Down

-$11,009

Down $33,004 (-150%) from 2016

Historical Trend

Balance Sheet Trend

Asset Growth37th percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$300K$200K$100K$0Assets 2010: $122,774Liabilities 2010: $3,159Net Assets 2010: $119,6152010Assets 2011: $164,391Liabilities 2011: $11,9462011Assets 2012: $185,924Liabilities 2012: $02012Assets 2013: $231,480Net Assets 2013: $231,4802013Assets 2014: $240,321Net Assets 2014: $240,3212014Assets 2015: $245,146Net Assets 2015: $245,1462015Assets 2016: $267,141Net Assets 2016: $267,1412016Assets 2017: $256,132Net Assets 2017: $256,1322017Assets 2018: $258,417Net Assets 2018: $258,4172018Assets 2019: $270,484Net Assets 2019: $270,4842019Assets 2020: $249,710Net Assets 2020: $249,7102020Assets 2021: $235,441Net Assets 2021: $235,4412021

Highlighted filing

2017

Assets$256,132
Liabilities-
Net Assets$256,132
Open 2017 Filing

Operations Trend

Revenue Growth42nd percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$150K$100K$50K$0-$50KRevenue 2010: $86,571Expenses 2010: $115,714Net Income 2010: -$29,1432010Revenue 2011: $98,828Expenses 2011: $65,998Net Income 2011: $32,8302011Revenue 2012: $61,379Expenses 2012: $27,900Net Income 2012: $33,4792012Revenue 2013: $86,547Expenses 2013: $40,991Net Income 2013: $45,5562013Revenue 2014: $38,327Expenses 2014: $29,486Net Income 2014: $8,8412014Revenue 2015: $46,413Expenses 2015: $41,588Net Income 2015: $4,8252015Revenue 2016: $37,707Expenses 2016: $15,712Net Income 2016: $21,9952016Revenue 2017: $36,304Expenses 2017: $47,313Net Income 2017: -$11,0092017Revenue 2018: $36,643Expenses 2018: $34,358Net Income 2018: $2,2852018Revenue 2019: $54,205Expenses 2019: $42,138Net Income 2019: $12,0672019Revenue 2020: $18,142Expenses 2020: $38,916Net Income 2020: -$20,7742020Revenue 2021: $219Expenses 2021: $14,488Net Income 2021: -$14,2692021

Highlighted filing

2017

Revenue$36,304
Expenses$47,313
Net Income-$11,009
Open 2017 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2017 to Dec 31, 2017
Signed
Nov 2, 2018
Return Version
2017v2.2
Gross Receipts
$36,304
Mission and Program Overview

Mission

The AIDS Treatment Activists Coalition (ATAC) is a national coalition of AIDS activists, many living with HIV/AIDS, working together to end the AIDS epidemic by advancing research on HIV/AIDS.

Program Services

DescriptionGrantsExpenses
Drug Development Committee (DDC):The Drug Development Committee is ATAC's principal committee. The DDC works with government, academia and industry to expedite and promote ethical HIV research. During 2017, the DDC engaged with every major HIV pharmaceutical company, including Gilead Sciences and TheraTechnologies.The topics of these conferences included the following:- New drugs in the pipeline with better efficacy, safety profiles and ease of administration.- Continuing safety and efficacy updates on approved drugs, including the status of post-marketing studies .- The design of clinical trials for both nave and heavily pre-treated HIV patients. - The necessity for inclusion of women, people of color and other underrepresented people in clinical trials and the necessity of conducting specific drug-drug interaction studies with new compounds to ensure underrepresented people will be eligible for trials and can participate safely; for example, interaction trials with hormonal contraceptives and methadone.- The need for collaboration among HIV drug companies so that fixed dosed combinations of the best drug cocktails will be available to people with HIV/AIDS- Expanded Access programs to make promising new drugs available to the multi-drug resistant patients that need new drugs the most.- New drugs in the pipeline for Hepatitis C (HCV), especially for individuals co-infected with HCV and HIV.- New strategies and therapies for eradicating HIV viral reservoirs, potentially leading to either a virtual cure or a sterilizing cure.Collaborations:The DDC continued working with other national and international AIDS advocacy groups, collaborating with the Treatment Action Group and Project Inform on HIV "Cure" Research and also with our European counterpart, the European Community Advisory Board (ECAB), part of the European AIDS Treatment Group. DDC members continue to participate with ECAB/EATG members in meetings with HIV drug companies. In addition, ATAC continues to build a collaborative relationship with the Martin Delaney Cure Collaboratories at various academic institutions across the United States.$44,799-
Compensation and Service Providers
Top Officer Pay76th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
MOISES AGOSTODirector-$0--
MURRAY PENNERDirector-$0--
MATTHEW ROSEDirector-$0--
DAVID PALMSecretary-$0--
MICHAEL DOROSHPresident-$0--
KEVIN FISHERVice President-$0--
ANDREW KAYTESTreasurer-$0--
JEFF TAYLORDirector-$0--
Filing and Contact Details

Filer

Filer Name
Aids Treatment Activists Coalition
EIN
57-1168208
Phone
3037777208
Address
PO BOX 9153, DENVER, CO 80209

Signing Officer

Name
Michael Dorosh
Title
Director
Signed
2018-11-02
Discuss with paid preparer
Yes

Preparer

Firm
Dinowitz & Bove CPAs
Address
150 Broadway Ste 1010, New York, NY 10038
Preparer
Frank Bove
Phone
2129730935
Supplemental Narrative

Additional Explanations

Other Expenses.1005

“Travel $20195”

Other Expenses.1007

“Conferences, Conventions, and Meetings $3368”

Other Expenses.1

“Lodging $14731”

Other Expenses.2

“Meals $6473”

Other Expenses.3

“Supplies $446”

Other Expenses.4

“Fees $228”

Other Expenses.5

“Telephone $95”

Raw XML Appendix167 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0MICHAEL DOROSH
IRS990EZ/BooksInCareOfDetail/PhoneNum03037777208
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt038 W MAPLE AVENUE
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0DENVER
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CO
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd080223
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt0267141
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt0256132
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt036100
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-11009
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt01745
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form720FiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0267141
IRS990EZ/Form990TotalAssetsGrp/EOYAmt0256132
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GrossReceiptsAmt036304
IRS990EZ/GrossReceiptsForPublicUseAmt00
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InitiationFeesAndCapContriAmt00
IRS990EZ/InvestmentIncomeAmt0204
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0267141
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0256132
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0267141
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0256132
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt01.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt11.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt21.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt31.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt41.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt51.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt61.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt71.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt70
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0MOISES AGOSTO
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1MURRAY PENNER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2MATTHEW ROSE
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3DAVID PALM
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4MICHAEL DOROSH
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5KEVIN FISHER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm6ANDREW KAYTES
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm7JEFF TAYLOR
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Secretary
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4President
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5Vice President
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt6Treasurer
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt7Director
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationFiled990TInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherExpensesTotalAmt045536
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0The AIDS Treatment Activists Coalition (ATAC) is a national coalition of AIDS activists, many living with HIV/AIDS, working together to end the AIDS epidemic by advancing research on HIV/AIDS.
IRS990EZ/PrintingPublicationsPostageAmt032
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0Drug Development Committee (DDC):The Drug Development Committee is ATAC's principal committee. The DDC works with government, academia and industry to expedite and promote ethical HIV research. During 2017, the DDC engaged with every major HIV pharmaceutical company, including Gilead Sciences and TheraTechnologies.The topics of these conferences included the following:- New drugs in the pipeline with better efficacy, safety profiles and ease of administration.- Continuing safety and efficacy updates on approved drugs, including the status of post-marketing studies .- The design of clinical trials for both nave and heavily pre-treated HIV patients. - The necessity for inclusion of women, people of color and other underrepresented people in clinical trials and the necessity of conducting specific drug-drug interaction studies with new compounds to ensure underrepresented people will be eligible for trials and can participate safely; for example, interaction trials with hormonal contraceptives and methadone.- The need for collaboration among HIV drug companies so that fixed dosed combinations of the best drug cocktails will be available to people with HIV/AIDS- Expanded Access programs to make promising new drugs available to the multi-drug resistant patients that need new drugs the most.- New drugs in the pipeline for Hepatitis C (HCV), especially for individuals co-infected with HCV and HIV.- New strategies and therapies for eradicating HIV viral reservoirs, potentially leading to either a virtual cure or a sterilizing cure.Collaborations:The DDC continued working with other national and international AIDS advocacy groups, collaborating with the Treatment Action Group and Project Inform on HIV "Cure" Research and also with our European counterpart, the European Community Advisory Board (ECAB), part of the European AIDS Treatment Group. DDC members continue to participate with ECAB/EATG members in meetings with HIV drug companies. In addition, ATAC continues to build a collaborative relationship with the Martin Delaney Cure Collaboratories at various academic institutions across the United States.
IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt044799
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/RelatedOrgSect527OrgInd0false
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0NY
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TotalExpensesAmt047313
IRS990EZ/TotalProgramServiceExpensesAmt044799
IRS990EZ/TotalRevenueAmt036304
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/WebsiteAddressTxt0www.aidstreatmentactivists.org
IRS990ScheduleA/FactsAndCircumstancesTestTxt0Prior Year Facts and Circumstances: The Organization will be maintaining a continuous and bona fide program for solicitation of funds from the general public involved.
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt036100
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt037500
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt046154
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt038000
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt086155
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt0243909
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt0204
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt0207
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt0259
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt0327
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt0392
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt01389
IRS990ScheduleA/OtherIncome170Grp/TotalAmt00
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.24840
IRS990ScheduleA/PublicSupportPY170Pct00.18190
IRS990ScheduleA/PublicSupportTotal170Amt060939
IRS990ScheduleA/SubstantialContributorsTotAmt0182970
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt00
IRS990ScheduleA/TenPctFactsCrcmstncsTestCYInd0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt036100
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt037500
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt046154
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt038000
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt086155
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt0243909
IRS990ScheduleA/TotalSupportAmt0245298
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt00
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Travel $20195
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Conferences, Conventions, and Meetings $3368
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2Lodging $14731
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3Meals $6473
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4Supplies $446
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt5Fees $228
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt6Telephone $95
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Other Expenses.1005
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Other Expenses.1007
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2Other Expenses.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3Other Expenses.2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4Other Expenses.3
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc5Other Expenses.4
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc6Other Expenses.5
ReturnHeader/BuildTS02019-02-21 02:37:17Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0MICHAEL DOROSH
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0Director
ReturnHeader/BusinessOfficerGrp/SignatureDt02018-11-02
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0AIDS TREATMENT ACTIVISTS COALITION
ReturnHeader/Filer/BusinessNameControlTxt0AIDS
ReturnHeader/Filer/EIN0571168208
ReturnHeader/Filer/PhoneNum03037777208
ReturnHeader/Filer/USAddress/AddressLine1Txt0PO BOX 9153
ReturnHeader/Filer/USAddress/CityNm0DENVER
ReturnHeader/Filer/USAddress/StateAbbreviationCd0CO
ReturnHeader/Filer/USAddress/ZIPCd080209
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0020632187
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0Dinowitz & Bove CPAs
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt0150 Broadway Ste 1010
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0New York
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0NY
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd010038
ReturnHeader/PreparerPersonGrp/PhoneNum02129730935
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0FRANK BOVE
ReturnHeader/PreparerPersonGrp/SelfEmployedInd0X
ReturnHeader/ReturnTs02018-11-02T17:55:22-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02017-01-01
ReturnHeader/TaxPeriodEndDt02017-12-31
ReturnHeader/TaxYr02017

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2017 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$256,132
Liabilities
-
Net assets
$256,132
Revenue
$36,304
Expenses
$47,313
Net income
-$11,009
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2021Detailed filing. Detailed filing data is available for this year.$2.35$2.35$0.00$0.14$0.14
2020Detailed filing. Detailed filing data is available for this year.$2.50$2.50$0.18$0.39$0.21
2019Detailed filing. Detailed filing data is available for this year.$2.70$2.70$0.54$0.42$0.12
2018Detailed filing. Detailed filing data is available for this year.$2.58$2.58$0.37$0.34$0.02
2017Detailed filing. Detailed filing data is available for this year.$2.56$2.56$0.36$0.47$0.11
2016Detailed filing. Detailed filing data is available for this year.$2.67$2.67$0.38$0.16$0.22
2015Detailed filing. Detailed filing data is available for this year.$2.45$2.45$0.46$0.42$0.05
2014Detailed filing. Detailed filing data is available for this year.$2.40$2.40$0.38$0.29$0.09
2013Detailed filing. Detailed filing data is available for this year.$2.31$2.31$0.87$0.41$0.46
2012Summary only. Only limited summary data is available for this year.$1.86$0.00$0.61$0.28$0.33
2011Summary only. Only limited summary data is available for this year.$1.64$0.12$0.99$0.66$0.33
2010Facts available. Structured filing facts are available, but richer extracted sections are limited.$1.23$0.03$1.20$0.87$1.16$0.29